Toll-like receptors and prostate cancer

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Zhao, Shu ^a,b   Zhang, Yifan ^a   Zhang, Qingyuan ^b   Wang, Fen ^a   Zhang, Dekai ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Immunotherapy; Innate immunity; Prostate cancer; TLR signaling; Toll like receptor

Indexed keywords

EID: 84905658804     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00352     Document Type: Review

References (78)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin (2014) 64(1):9-29. doi: 10.3322/caac.21208
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013
3. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 7(4):256-69. doi:10.1038/nrc2090
4. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol (2003) 21:335-76. doi:10.1146/annurev.immunol.21.120601.141126
5. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol (1989) 54(Pt 1):1-13. doi:10.1101/SQB.1989.054.01.003
6. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282(5396):2085-8. doi:10.1126/science.282.5396.2085
7. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science (1999) 285(5428):736-9. doi:10.1126/science.285.5428.736
8. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A toll-like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740-5. doi:10.1038/35047123
9. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature (2001) 413(6857):732-8. doi:10.1038/35099560
10. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature (2001) 410(6832):1099-103. doi:10.1038/35074106
11. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 303(5663):1526-9. doi:10.1126/science.1093620
12. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol (2005) 174(5):2942-50. doi:10.4049/jimmunol.174.5.2942
13. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 168(9):4531-7. doi:10.4049/jimmunol.168.9.4531
14. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem (2007) 76:447-80. doi:10.1146/annurev.biochem.76.060605.122847
15. Salaun B, Romero P, Lebecque S. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol (2007) 37(12):3311-8. doi:10.1002/eji.200737744
16. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 5(10):987-95. doi:10.1038/ni1112
17. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13(9):1050-9. doi:10.1038/nm1622
18. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 457(7225):102-6. doi:10.1038/nature07623
19. Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA, Gollnick SO. Peroxiredoxin 1 controls prostate cancer growth through toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res (2011) 71(5):1637-46. doi:10.1158/0008-5472.CAN-10-3674
20. Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother (2012) 61(5):667-76. doi:10.1007/s00262-011-1132-1
21. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis (2008) 29(7):1334-42. doi:10.1093/carcin/bgn149
22. Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A, et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia (2010) 12(7):539-49. doi:10.1593/neo.92106
23. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, Aguirre A, Suarez A, Gonzalez JM, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother (2011) 60(2):217-26. doi:10.1007/s00262-010-0931-0
24. Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res (2010) 70(7):2595-603. doi:10.1158/0008-5472.CAN-09-1162
25. Galli R, Starace D, Busa R, Angelini DF, Paone A, De Cesaris P, et al. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J Immunol (2010) 184(12):6658-69. doi:10.4049/jimmunol.0902401
26. Quintar AA, Roth FD, De Paul AL, Aoki A, Maldonado CA. Toll-like receptor 4 in rat prostate: modulation by testosterone and acute bacterial infection in epithelial and stromal cells. Biol Reprod (2006) 75(5):664-72. doi:10.1095/biolreprod.106.053967
27. Gatti G, Rivero V, Motrich RD, Maccioni M. Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and proinflammatory mediators upon LPS stimulation. J Leukoc Biol (2006) 79(5):989-98. doi:10.1189/jlb.1005597
28. Pei Z, Lin D, Song X, Li H, Yao H. TLR4 signaling promotes the expression of VEGF and TGFbeta1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cell Immunol (2008) 254(1):20-7. doi:10.1016/j.cellimm.2008.06.007
29. Gatti G, Quintar AA, Andreani V, Nicola JP, Maldonado CA, Masini-Repiso AM, et al. Expression of toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate (2009) 69(13):1387-97. doi:10.1002/pros.20984
30. Vaisanen MR, Vaisanen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS, et al. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate (2010) 70(8):817-24. doi:10.1002/pros.21115
31. Di JM, Pang J, Sun QP, Zhang Y, Fang YQ, Liu XP, et al. Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells. Mol Biol Rep (2010) 37(4):1849-55. doi:10.1007/s11033-009-9620-5
32. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate (2007) 67(7):774-81. doi:10.1002/pros.20562
33. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 5(7):522-31. doi:10.1038/nrg1415
34. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature (2005) 435(7043):834-8. doi:10.1038/nature03702
35. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 6(11):857-66. doi:10.1038/nrc1997
36. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res (2006) 66(15):7390-4. doi:10.1158/0008-5472.CAN-06-0800
37. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 6(4):259-69. doi:10.1038/nrc1840
38. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 10(10):704-14. doi:10.1038/nrg2634
39. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med (2009) 60:167-79. doi:10.1146/annurev.med.59.053006.104707
40. Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol (2007) 302(1):1-12. doi:10.1016/j.ydbio.2006.08.028
41. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev (2009) 28(3-4):369-78. doi:10.1007/s10555-009-9188-5
42. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 136(4):586-91. doi:10.1016/j.cell.2009.02.005
43. Nahid MA, Satoh M, Chan EK. MicroRNA in TLR signaling and endotoxin tolerance. Cell Mol Immunol (2011) 8(5):388-403. doi:10.1038/cmi.2011.26
44. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of toll-like receptor signalling. Nat Rev Immunol (2011) 11(3):163-75. doi:10.1038/nri2957
45. Quinn SR, O'Neill LA. A trio of microRNAs that control toll-like receptor signalling. Int Immunol (2011) 23(7):421-5. doi:10.1093/intimm/dxr034
46. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, et al. MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 109(31):E2110-6. doi:10.1073/pnas.1209414109
47. He X, Jing Z, Cheng G. MicroRNAs: new regulators of toll-like receptor signalling pathways. Biomed Res Int (2014) 2014:945169. doi:10.1155/2014/945169
48. Ahmed F, Shiraishi T, Vessella RL, Kulkarni P. Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. Oncol Rep (2013) 30(6):2963-8. doi:10.3892/or.2013.2789
49. Galli R, Paone A, Fabbri M, Zanesi N, Calore F, Cascione L, et al. Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARbeta and tumor regression. Proc Natl Acad Sci U S A (2013) 110(24):9812-7. doi:10.1073/pnas.1304610110
50. Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, et al. Small interfering RNA-directed targeting of toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol (2009) 46(15):2876-84. doi:10.1016/j.molimm.2009.06.016
51. Sun J, Wiklund F, Zheng SL, Chang B, Balter K, Li L, et al. Sequence variants in toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst (2005) 97(7):525-32. doi:10.1093/jnci/dji070
52. Stevens VL, Hsing AW, Talbot JT, Zheng SL, Sun J, Chen J, et al. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer (2008) 123(11):2644-50. doi:10.1002/ijc.23826
53. Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res (2004) 64(8):2918-22. doi:10.1158/0008-5472.CAN-03-3280
54. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res (2005) 65(24):11771-8. doi:10.1158/0008-5472.CAN-05-2078
55. Cheng I, Plummer SJ, Casey G, Witte JS. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 16(2):352-5. doi:10.1158/1055-9965.EPI-06-0429
56. Song J, Kim DY, Kim CS, Kim HJ, Lee DH, Lee HM, et al. The association between toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet (2009) 190(2):88-92. doi:10.1016/j.cancergencyto.2008.12.011
57. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate (2009) 69(8):874-85. doi:10.1002/pros.20933
58. Kim HJ, Bae JS, Chang IH, Kim KD, Lee J, Shin HD, et al. Sequence variants of Toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol (2012) 30(2):225-32. doi:10.1007/s00345-011-0690-3
59. Shui IM, Stark JR, Penney KL, Schumacher FR, Epstein MM, Pitt MJ, et al. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate (2012) 72(2):209-16. doi:10.1002/pros.21423
60. Chen YC, Giovannucci E, Kraft P, Lazarus R, Hunter DJ. Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 16(10):1982-9. doi:10.1158/1055-9965.EPI-07-0325
61. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial watch: FDA-approved toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1(6):894-907. doi:10.4161/onci.20931
62. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science (2007) 316(5831):1628-32. doi:10.1126/science.1138963
63. Schiffman M, Wacholder S. Success of HPV vaccination is now a matter of coverage. Lancet Oncol (2012) 13(1):10-2. doi:10.1016/S1470-2045(11)70324-2
64. van Egmond S, Hoedemaker C, Sinclair R. Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol (2007) 46(3):318-9. doi:10.1111/j.1365-4632.2007.03200.x
65. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 3(2):196-200. doi:10.1038/ni758
66. Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology (2012) 1(9):1661-3. doi:10.4161/onci.22033
67. Hennessy EJ, Parker AE, O'Neill LA. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov (2010) 9(4):293-307. doi:10.1038/nrd3203
68. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev (2009) 61(2):177-97. doi:10.1124/pr.109.001073
69. Han JH, Park SY, Kim JB, Cho SD, Kim B, Kim BY, et al. TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells. Am J Reprod Immunol (2013) 70(4):317-26. doi:10.1111/aji.12146
70. Han JH, Lee J, Jeon SJ, Choi ES, Cho SD, Kim BY, et al. In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod. Int J Oncol (2013) 42(6):2087-93. doi:10.3892/ijo.2013.1898
71. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial watch: experimental toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1(5):699-716. doi:10.4161/onci.20696
72. Brodsky I, Strayer DR, Krueger LJ, Carter WA. Clinical studies with ampligen (mismatched double-stranded RNA). J Biol Response Mod (1985) 4(6):669-75.
73. Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother (2013) 62(6):1041-52. doi:10.1007/s00262-013-1415-9
74. Zhang Y, Wang Y, Yuan J, Qin W, Liu F, Wang F, et al. Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells. Cell Biol Toxicol (2012) 28(4):269-77. doi:10.1007/s10565-012-9221-2
75. Kutikhin AG, Yuzhalin AE. Are toll-like receptor gene polymorphisms associated with prostate cancer? Cancer Manag Res (2012) 4:23-9. doi:10.2147/CMAR.S28683
76. Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, Berndt SI, et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers - results from BPC3. PLoS One (2011) 6(2):e17142. doi:10.1371/journal.pone.0017142
77. Malara AE, Fedele C, Aloj L, Arra C, Laccetti P, D'Alessio G, et al. Effects of a human compact anti-ErbB2 antibody on prostate cancer. Oncol Rep (2012) 28(1):297-302. doi:10.3892/or.2012.1760
78. Gora J, Hopfgartner J, Kuess P, Paskeviciute B, Georg D. Is there room for combined modality treatments? Dosimetric comparison of boost strategies for advanced head and neck and prostate cancer. J Radiat Res (2013) 54(Suppl 1):i97-112. doi:10.1093/jrr/rrt067